DIAXONHIT - BJI InoPlex(TM) test: Completion of patients

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DIAXONHIT - BJI InoPlex(TM) test: Completion of patients enrollment in the final validation study of the first diagnostic test for prosthetic bone and joint infections
  • Final performance and CE marking expected before the end of 2014
     
  • Commercial launch early 2015, strengthening Diaxonhit's diagnostic product offering in infectious diseases

PARIS, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Diaxonhit (Alternext : ALEHT, FR0004054427), a French leader in specialty in-vitro diagnostics, announces the completion of patient enrollment in its validation study of BJI InoPlex(TM), the first blood test for the diagnosis of hip and knee replacement infections.

This validation study of the performance and clinical utility of the test was held in two reference centers for bone and joint Infections (CRIOA) in the Ile-de-France region (Croix Saint-Simon and Ambroise Pare hospitals). 470 patients were enrolled, including 200 patients whose prostheses were infected. The results of the study are currently being analyzed, and the final performance of BJI InoPlex(TM) is expected for the last quarter of 2014. CE marking the test is scheduled for December 2014.

BJI InoPlex(TM) would then be the first non-invasive blood test to support the diagnosis of prosthetic bone and joint infections. Through a simple process, it facilitates confirmation of an infection or not.

Every year, approximately 3 million prostheses are implanted in Europe and the United States 1 . In France, approximately 221,000 hip and knee replacements were performed in 2012 2 . This market is growing due to aging and growing obesity. Nearly 20% of all patients who undergo prosthetic surgery experience pain within a few days to a few months, and identification of its cause - mechanical or infectious - is a long, invasive and tedious process. Prosthetic infection is indeed a serious complication that requires rapid and relevant therapy including surgery and long-term antibiotic treatment to prevent chronic infection and severe sequelae. Identifying infections is also important to avoid administration of unnecessary antibiotics to patients whose pain is due to mechanical causes.

" Currently, the diagnosis of prosthetic infections is still too long. None of the available tools, whether clinical, radiological or biological, have a sensitivity and specificity of 100%. BJI InoPlex(TM) would complement and enrich this diagnostic arsenal by providing a quick response on the immune status of the patient with respect to the main pathogens found in this type of infection. This test should therefore improve the reliability of differential diagnosis between mechanical failure and prosthetic infection. It could also be quite useful for prognostic considerations as well as therapeutic follow-up" , says Professor Jean-Louis Gaillard, head of the biology division of University Hospitals Paris Ile-de-France Ouest. 

" BJI InoPlex is a blood test designed to provide orthopedic surgeons with a simple and non-invasive diagnostic complement. Once the final results of the study known in the next few weeks, BJI InoPlex would be the first blood test on the market to address this largely unmet medical need. This innovative test should strengthen our specialty in-vitro diagnostic offering in the field of infectious diseases, and extend our leadership beyond the transplantation market. " concludes Loïc Maurel, M.D., President of the Management Board of Diaxonhit.

About BJI InoPlex(TM)

BJI InoPlex (TM) is a multiplex assay based on the detection in patient's blood of antibodies targeting key bacterial antigens recognized by the immune system during prosthetic infections. Developed on the Luminex technology and using highly specific recombinant antigens, this test allows individual and simultaneous characterization of antibodies targeting four families of bacteria including staphylococci that represents 80% of infections. It requires a very small amount of serum obtained by simple blood draw and can be easily repeated. BJI InoPlex (TM) is protected by several patents covering selected antigens as well as the algorithm for interpretation of results.

About DIAXONHIT

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in the in vitro diagnostic field, involved from research to commercialization of specialty diagnostic products. With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in-vitro diagnostic kits and advanced equipment. It operates mainly in the fields of transplantation, infectious diseases and autoimmunity, product quality control and rapid tests, including Tetanus Quick Stick ®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo-Fisher/One Lambda, of which it is the largest distributor worldwide. The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering three main specialty areas: transplantation, immuno-infection and cancer. Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index.

For more information, please visit: http://www.diaxonhit.com

Symbol: ALEHT - ISIN Code: FR0004054427  -  Reuters: ALEHT.PA  - Bloomberg: ALEHT:FP

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, Diaxonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

Contacts

DIAXONHIT

Hervé Duchesne de Lamotte, CFO, +33 (0)1 53 94 52 49, herve.delamotte@diaxonhit.com

NewCap

Julien Perez, Investors Relations & Financial Communication, +33 (0)1 44 71 98 52, jperez@newcap.fr

Annie-Florence Loyer, Media Relations, +33 (0)1 44 71 98 50, afloyer@newcap.fr

1 Strategic insights into the orthopaedic industry, June 2012

2 French Health Authority (HAS)

Press release http://hugin.info/159969/R/1858120/650723.pdf

HUG#1858120

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 120

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 65

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 46

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 42

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 100

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 143

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 139

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 75

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading

Top 5 Most Recently Viewed Articles

Twist Bioscience Set to Showcase Innovations at J.P. Morgan Event

Updated Category News Views 105

Twist Bioscience to Present at Renowned Healthcare Conference Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in the synthetic biology and genomics field, has announced an upcoming presentation at the annual J.P. Morgan Healthcare Conference. This significant event is slated for January, and it serves as a vital platform for the company to showcase its...

Continue Reading
Leidos Secures Major NSA Contract Worth $390 Million

Updated Category News Views 154

Leidos Wins $390 Million NSA Signals Intelligence Contract Leidos, a prominent player in the defense and technology sectors, has recently secured a significant contract to enhance the capabilities of the National Security Agency (NSA) in the field of signals intelligence (SIGINT). This contract, valued at $390 million, will span an initial year with four additional...

Continue Reading
Devin Shanahan's Strategic Innovations in Global Trade Adaptation

Updated Category News Views 165

Adapting to Global Trade Challenges In a rapidly changing trade landscape, Devin Shanahan, co-founder of the innovative consumer brand Funtazma, is leading thoughtful changes in supply chain management due to the growing impact of U.S.-China trade tensions. With a wealth of experience in scaling consumer brands through global sourcing, Shanahan has been pivotal in guiding...

Continue Reading
Animal Nutrition Chemicals Market Insights and Growth Prospects

Updated Category News Views 185

Animal Nutrition Chemicals Market Overview The rapidly evolving animal nutrition chemicals market is poised for remarkable growth. As the need for high-quality and nutritious animal feed continues to escalate, this sector is likely to see significant changes and expansion. Comprehensive analyses reveal a bright future as industry players adapt to shifting demands and...

Continue Reading
Investors Ensnared in Orthofix Securities Fraud Case Seek Justice

Updated Category News Views 49

Understanding the Orthofix Securities Fraud Case Recently, investors in Orthofix Medical Inc. were informed about a serious legal action involving alleged securities fraud. The Schall Law Firm, which advocates for shareholder rights, is leading a class action lawsuit that addresses the alleged missteps by Orthofix during a specific time frame. It’s important for...

Continue Reading